Considering that beyond the inhibition of cell proliferation, the CDK4/6 inhibitors may exert other effects on cancer cells such as the induction of a senescent-like phenotype [11], we tested the production of the Senescent-Associated β-galactosidase enzyme (SA-β-Gal) in these resistant cell models. The gene discussed is CDK4; the disease is cancer.